Robert W. Baird Has Lowered Expectations for DexCom (NASDAQ:DXCM) Stock Price

Key Points

• Robert W. Baird has lowered its target price for DexCom (NASDAQ:DXCM) stock from $112.00 to $90.00 while maintaining an "outperform" rating, suggesting a potential upside of 31.77% from the stock's prior close.
• Other analysts have varied opinions, with UBS raising their target to $106.00 and Piper Sandler increasing theirs to $100.00, indicating a generally positive outlook for the stock.
• DexCom recently reported earnings that beat analysts' expectations, with a 15.2% revenue increase compared to the same quarter last year, further solidifying its position in the medical device market.

DexCom (NASDAQ:DXCM - Get Free Report) had its target price lowered by equities research analysts at Robert W. Baird from $112.00 to $90.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an "outperform" rating on the medical device company's stock. Robert W. Baird's price target would indicate a potential upside of 31.77% from the stock's previous close.

Several other equities analysts have also weighed in on DXCM. UBS Group increased their price target on shares of DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. Wall Street Zen downgraded shares of DexCom from a "strong-buy" rating to a "buy" rating in a research report on Sunday, August 10th. Piper Sandler upped their target price on shares of DexCom from $90.00 to $100.00 and gave the company an "overweight" rating in a research note on Thursday, July 31st. William Blair upgraded shares of DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Finally, Mizuho upped their price objective on DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $99.11.

DexCom Price Performance

NASDAQ:DXCM opened at $68.30 on Friday. The stock's 50 day moving average price is $78.61 and its two-hundred day moving average price is $78.03. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $26.78 billion, a price-to-earnings ratio of 47.43, a P/E/G ratio of 1.42 and a beta of 1.48. DexCom has a 12-month low of $57.52 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the company posted $0.43 EPS. The company's revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. On average, analysts anticipate that DexCom will post 2.03 earnings per share for the current year.

Insider Buying and Selling

In other DexCom news, Director Kyle Malady sold 667 shares of the company's stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the transaction, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president directly owned 105,223 shares of the company's stock, valued at $8,417,840. The trade was a 1.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,849 shares of company stock valued at $564,733 in the last ninety days. Insiders own 0.32% of the company's stock.

Hedge Funds Weigh In On DexCom

Large investors have recently made changes to their positions in the stock. Andra AP fonden acquired a new position in DexCom during the 2nd quarter worth approximately $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in DexCom during the 2nd quarter worth approximately $26,000. Golden State Wealth Management LLC increased its holdings in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares during the period. Zions Bancorporation National Association UT purchased a new stake in shares of DexCom during the first quarter worth approximately $27,000. Finally, Anderson Financial Strategies LLC purchased a new position in DexCom in the 1st quarter valued at $37,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.